LASA · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 20/100 — Quality 29 · Momentum 0
| Share price | ₹7.13 |
| Market cap | ₹38 Cr |
| P/B ratio | 0.8 |
| ROE | -68.0% |
| ROCE | -69.1% |
| Book value | ₹9.89 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹25 Cr | ₹-34 Cr | -53.2% |
| 2025 | ₹142 Cr | ₹-15 Cr | -4.2% |
| 2024 | ₹104 Cr | ₹-22 Cr | -8.2% |
| 2023 | ₹130 Cr | ₹-39 Cr | -14.0% |
| 2022 | — | — | — |
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports i